The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is a huge mover today! The stock increased 6.77% or $0.7 on November 7, hitting $11.04. About 109,716 shares traded hands. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 0.88% since April 5, 2016 and is uptrending. It has underperformed by 1.08% the S&P500.
The move comes after 6 months positive chart setup for the $242.10 million company. It was reported on Nov, 7 by Barchart.com. We have $32.68 PT which if reached, will make NASDAQ:AQXP worth $474.52M more.
Analysts await Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to report earnings on November, 8. They expect $-0.62 EPS, down 44.19% or $0.19 from last year’s $-0.43 per share. After $-0.63 actual EPS reported by Aquinox Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -1.59% EPS growth.
Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage
Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) earned “Outperform” rating by Leerink Swann on Monday, September 21. Jefferies maintained Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) on Friday, August 5 with “Hold” rating. As per Tuesday, October 6, the company rating was initiated by Guggenheim. Canaccord Genuity maintained it with “Hold” rating and $22 target price in Friday, September 11 report. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. Needham initiated the stock with “Buy” rating in Friday, October 23 report.
According to Zacks Investment Research, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.”
More recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: Marketwatch.com which released: “Aquinox Pharmaceuticals stock skyrockets 450%” on August 07, 2015. Also Marketwatch.com published the news titled: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. Etfdailynews.com‘s news article titled: “Aquinox Pharmaceuticals Inc (AQXP): How This Biotech Stock Trapped Investors” with publication date: August 17, 2015 was also an interesting one.
AQXP Company Profile
Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.